Taiho Pharmaceutical has invested in a series A round for the small-molecule therapy developer that now totals $21.6m.
UK-based small-molecule therapeutics developer Storm Therapeutics increased its series A round to £16m ($21.6m) yesterday with funding from Taiho Ventures, the corporate venturing arm of pharmaceutical company Taiho Pharmaceutical.
Storm received the first £12m from Merck Ventures and Pfizer Venture Investments, respective subsidaries of pharmaceutical firms Merck Group and Pfizer, Touchstone Innovations and Cambridge Innovation Capital in June 2016.
Storm Therapeutics is developing medicines that will treat cancer and other diseases by modulating the enzymes that modify RNAs, the…